SCHEMBL4393706

SCHEMBL4393706

CC(C)NCCCC(N)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
ARG1 P05089 1/20 0.38
ARG2 P78540 1/20 0.38
ALDH1A1 P00352 4/20 0.35
ECE1 P42892 1/20 0.35
DPP4 P27487 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
KDM4E B2RXH2 4/20 0.34
KMT2A Q03164 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
MEN1 O00255 1/20 0.33
FAAH O00519 1/20 0.33
MAPK1 P28482 1/20 0.33
ALOX15 P16050 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33
ADRB2 P07550 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15602554 0.93 ARG1 (0.37) SLC6A2SLC6A4SLC6A3ARG1ARG2
SCHEMBL24359721 0.91 MEN1 (0.39) SLC6A2SLC6A4SLC6A3ARG1ARG2
SCHEMBL22730909 0.91 MEN1 (0.39) SLC6A2SLC6A4SLC6A3ARG1ARG2
SCHEMBL3321078 0.88
SCHEMBL329452 0.83 ARG1 (0.35) ARG1ARG2ALDH1A1KDM4EKMT2A
SCHEMBL11670295 0.81 ARG1 (0.33) SLC6A2SLC6A4SLC6A3ARG1ARG2
SCHEMBL5255471 0.81 LMNA (0.46) ALDH1A1KMT2ATDP1MEN1ALOX15
SCHEMBL5255466 0.81 ALDH1A1 (0.34) ARG1ARG2ALDH1A1KDM4EKMT2A
SCHEMBL10125881 0.81 ALDH1A1 (0.41) ARG1ARG2ALDH1A1KDM4EKMT2A
SCHEMBL960791 0.80 CTSD (0.46) ARG1ARG2ALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023122298-A1 PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS Stablix, Inc. (US) 2023-06-29 WO disclosed
US-20100029637-A1 Chymase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-04 US disclosed
EP-1756046-B1 ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS UNIV ABERDEEN (GB) 2009-12-09 EP disclosed
US-20080119555-A1 Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2008-05-22 US disclosed
EP-1756046-A2 ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS The University Court of The University of Aberdeen (GB) 2007-02-28 EP disclosed
WO-2005118528-A2 ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029637-A1 Chymase Inhibitors CMA1, CPA3, SERPINB1 SLC6A2 2830/4885SLC6A4 2736/4885SLC6A3 3621/4885
US-20080119555-A1 Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions ARSA, CNKSR1, BCL9L SLC6A2 2563/4885SLC6A4 2261/4885SLC6A3 2163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.